EMV Capital 将来の成長

Future 基準チェック /26

EMV Capitalは収益が増加すると予測されています。

主要情報

n/a

収益成長率

n/a

EPS成長率

Medical Equipment 収益成長	22.5%
収益成長率	49.2%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	07 Nov 2024

今後の成長に関する最新情報

Recent updates

Shareholders Will Probably Hold Off On Increasing NetScientific plc's (LON:NSCI) CEO Compensation For The Time Being

Jul 03

Would NetScientific (LON:NSCI) Be Better Off With Less Debt?

Nov 03

NetScientific plc (LON:NSCI) Insiders Increased Their Holdings

Feb 18

業績と収益の成長予測

AIM:EMVC - アナリストの将来予測と過去の財務データ ( )GBP Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	3,419	N/A	48	N/A	1
12/31/2025	3,274	N/A	-2,383	N/A	1
12/31/2024	2,682	N/A	-975	N/A	1
6/30/2024	2	-3	-3	-2	N/A
3/31/2024	2	-3	-3	-3	N/A
12/31/2023	1	-3	-3	-3	N/A
9/30/2023	1	-3	-3	-3	N/A
6/30/2023	1	-3	-3	-3	N/A
3/31/2023	1	-3	-3	-3	N/A
12/31/2022	1	-3	-3	-3	N/A
9/30/2022	1	-3	-3	-3	N/A
6/30/2022	1	-3	-4	-3	N/A
3/31/2022	1	-2	-4	-3	N/A
12/31/2021	1	-2	-4	-3	N/A
9/30/2021	1	-2	-3	-3	N/A
6/30/2021	1	-2	-3	-3	N/A
3/31/2021	1	-2	-3	-3	N/A
12/31/2020	0	-2	-3	-3	N/A
9/30/2020	1	-2	-3	-2	N/A
6/30/2020	1	-2	-2	-2	N/A
3/31/2020	1	-3	-3	-3	N/A
12/31/2019	1	-3	-4	-4	N/A
6/30/2019	0	-3	-7	-7	N/A
3/31/2019	0	-3	-8	-8	N/A
12/31/2018	0	-3	-8	-8	N/A
6/30/2018	0	0	-9	-9	N/A
3/31/2018	0	-2	N/A	-10	N/A
12/31/2017	0	-3	N/A	-11	N/A
9/30/2017	0	-9	N/A	-11	N/A
6/30/2017	0	-10	N/A	-12	N/A
3/31/2017	0	-10	N/A	-12	N/A
12/31/2016	1	-11	N/A	-13	N/A
9/30/2016	0	-10	N/A	-13	N/A
6/30/2016	0	-10	N/A	-12	N/A
3/31/2016	0	-9	N/A	-12	N/A
12/31/2015	0	-9	N/A	-11	N/A
6/30/2015	0	-7	N/A	-9	N/A
3/31/2015	0	-6	N/A	-8	N/A
12/31/2014	N/A	-5	N/A	-7	N/A
9/30/2014	N/A	-6	N/A	-6	N/A
6/30/2014	N/A	-5	N/A	-6	N/A
3/31/2014	N/A	-5	N/A	-5	N/A

アナリストによる今後の成長予測

収入対貯蓄率: EMVCの予測収益成長が貯蓄率 ( 2.1% ) を上回っているかどうかを判断するにはデータが不十分です。

収益対市場: EMVCの収益がUK市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です

高成長収益: EMVCの収益が今後 3 年間で大幅に増加すると予想されるかどうかを判断するにはデータが不十分です。

収益対市場: EMVCの収益 ( 49.2% ) UK市場 ( 3.5% ) よりも速いペースで成長すると予測されています。

高い収益成長: EMVCの収益 ( 49.2% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: EMVCの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

EMV Capital 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Price target increased to UK£2.00

Recent updates

First half 2024 earnings released: UK£0.071 loss per share (vs UK£0.058 loss in 1H 2023)

New minor risk - Shareholder dilution

New major risk - Revenue and earnings growth

Shareholders Will Probably Hold Off On Increasing NetScientific plc's (LON:NSCI) CEO Compensation For The Time Being

New minor risk - Shareholder dilution

NetScientific plc, Annual General Meeting, Jul 10, 2024

Full year 2023 earnings released: UK£0.11 loss per share (vs UK£0.14 loss in FY 2022)

NetScientific plc to Report Fiscal Year 2023 Results on Jun 13, 2024

New minor risk - Financial data availability

New minor risk - Shareholder dilution

Pds Biotech Announces Updated Survival Data from Nci-Led Phase 2 Clinical Trial of Pds0101-Based Triple Combination Therapy in Advanced Hpv16-Positive Cancer Patients

Would NetScientific (LON:NSCI) Be Better Off With Less Debt?

First half 2023 earnings released: UK£0.058 loss per share (vs UK£0.066 loss in 1H 2022)

NetScientific plc, Annual General Meeting, Jun 29, 2023

Full year 2022 earnings released: UK£0.14 loss per share (vs UK£0.13 loss in FY 2021)

NetScientific plc Announces Board Changes

Netscientific plc Announces Board Changes

NetScientific plc Announces the Completion of Enrolment in the First Stage of the Checkpoint Inhibitor Refractory Group of Its Versatile-002 Phase 2 Study for the Potential Treatment of Recurrent And/Or Metastatic Human Papillomavirus (Hpv16)-Positive Head and Neck Cancer

NetScientific plc Announces Board Changes

No independent directors

NetScientific plc Announces Board Changes

Full year 2021 earnings: EPS and revenues miss analyst expectations

Price target increased to UK£2.00

NetScientific plc (AIM:NSCI) completed the acquisition of 30% stake in Vortex Biotech Holdings Ltd.

NetScientific plc has completed a Follow-on Equity Offering in the amount of £1.499996 million.

NetScientific plc, Annual General Meeting, Jun 29, 2022

NetScientific plc, Annual General Meeting, Jun 29, 2022

Full year 2021 earnings: EPS and revenues miss analyst expectations

NetScientific plc to Report Fiscal Year 2021 Results on May 12, 2022

NetScientific plc (AIM:NSCI) entered into a agreement to acquire 30% stake in Vortex Biotech Holdings Ltd for £0.3 million.

No independent directors

NetScientific plc (AIM:NSCI) acquired 75% stake in Cetromed Limited from Zahra Holdings Limited for £0.19 million.

First half 2021 earnings released: UK£0.079 loss per share (vs UK£0.11 loss in 1H 2020)

NetScientific plc has completed a Follow-on Equity Offering in the amount of £7.74556 million.

Full year 2020 earnings released: UK£0.11 loss per share (vs UK£0.40 loss in FY 2019)

Full year 2020 earnings released: UK£0.029 loss per share (vs UK£0.40 loss in FY 2019)

NetScientific plc (LON:NSCI) Insiders Increased Their Holdings

NetScientific plc Confirms Appointment of Stephen Crowe as Chief Financial Officer

NetScientific plc (AIM:NSCI) agreed to acquire remaining 43.6% stake in ProAxsis Ltd from Qubis Limited and the founders (sellers) for £0.23 million.

NetScientific plc (AIM:NSCI) completed the acquisition of EMV Capital Ltd from Futura Messis Group Ltd.

NetScientific plc has completed a Follow-on Equity Offering in the amount of £2.299996 million.

An unknown buyer acquire 9.55% minority stake in NetScientific plc (AIM:NSCI) from Acacia Research Corporation (NasdaqGS:ACTG).

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘